---
title: Stabilize heart and blood pressure
nct_id: NCT07084597
phase: NA
status: RECRUITING
sponsor: Bangladesh Medical University
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07084597"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07084597"
last_fetched: "2026-05-10T14:06:52.945Z"
source: "Parkinson's Pathways (curated)"
---
# Stabilize heart and blood pressure

**Goal (in five words):** Stabilize heart and blood pressure

**Official Title:** Effect of Vitamin D3 Supplementation on Cardiac Autonomic Nerve Function in Male

**Trial ID:** [NCT07084597](https://clinicaltrials.gov/study/NCT07084597)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Bangladesh Medical University
- **Target Enrollment:** 15 participants
- **Start Date:** 2025-07
- **Completion Date:** 2025-10
- **Conditions:** Parkinson Disease
- **Interventions:** Vitamin D
- **Intervention Types:** DIETARY_SUPPLEMENT

## Summary For Families

It's testing whether correcting vitamin D3 deficiency can improve cardiac autonomic nerve function, which in Parkinson's can show up as abnormal heart rate variability and blood pressure changes. Participants will take vitamin D3 to raise blood levels, because vitamin D helps regulate calcium balance and has anti-inflammatory and neuroprotective effects that may stabilize autonomic signaling to the heart, and the supplement is given alongside levodopa while calcium levels are monitored. Men aged 51 to 70 with mild to moderate Parkinson's (Hoehn and Yahr I,III), BMI 18.5,24.9, who are vitamin D deficient or insufficient and are taking levodopa are eligible. People with major organ disease, hypercalcemia, current use of antioxidant vitamins or certain heart, blood pressure or sedative drugs, or those already doing yoga or breathing exercises are excluded.

## Eligibility

- **Minimum age:** 51 Years
- **Maximum age:** 70 Years
- **Sex:** MALE

### Full Criteria

```
IInclusion criteria:

* Male patients with of Parkinson's disease diagnosed by neurologist with unilateral or bilateral involvement and mild to moderate disability according to Hoehn and Yahr (H-Y) scale (I-III)
* Age: 51-70 years
* BMI: 18.5-24.9 kg/m2
* Vitamin D3 deficient or insufficient
* On Levodopa medication

Exclusion criteria:

1. Patients with a history of drug abuse including alcoholism.
2. Patients on following drugs will be excluded-

   * Antioxidant vitamin supplements
   * Lipid lowering medications
   * Antihypertensive drug
   * Anti-arrhythmic drug
   * Sedatives
3. All patients with the history of or clinical manifestation of currently suffering from following diseases \& condition will be excluded

   * Severe Cardiovascular disorders
   * Severe neurological disorders
   * Severe Respiratory disorders
   * Severe Renal insufficiency (S. Creatinine \> 1.5 mg/dl, Acute or chronic kidney disease)
   * Severe Endocrine disease
   * Severe Arthritis
   * Severe Liver diseases
   * Severe Neoplastic disease
   * Severe Psychiatric disorder
   * Current use of iron, zinc, calcium, magnesium and multivitamin supplementation
   * Already performing yoga or breathing exercise
   * Hypercalcemia
```

## Locations (1)

- Bangladesh Medical University, Dhaka, Shahbag, Bangladesh _(23.7104, 90.4074)_
  - Jobayda Jobayda, MBBS,MD(Phase B) — (PRINCIPAL_INVESTIGATOR)

## Central Contacts

- Registrar BMU — (CONTACT) — +880255165708 — registrar@bsmmu.edu.bd
- Jobayda Jobayda, MBBS,MD resident,Phase B — (CONTACT) — 01773845305 — jbinterohmotullah@gmail.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT07084597*  
*HTML version: https://parkinsonspathways.com/trial/NCT07084597*  
*Source data: https://clinicaltrials.gov/study/NCT07084597*